Gabapentin and Delirium Risk
Yes, gabapentin can contribute to delirium, particularly in older adults and those with high comorbidity burden, and this risk should be carefully weighed against potential benefits when prescribing for pain management.
Evidence from FDA Labeling
The FDA label for gabapentin explicitly warns about central nervous system effects that overlap with delirium symptoms 1. Gabapentin causes somnolence (19% vs 9% placebo), dizziness (17% vs 7% placebo), and ataxia in controlled trials 1. More concerning, the label specifically warns about "changes in behavior and thinking" in children, including emotional changes, aggressive behavior, problems with concentration, and restlessness 1. These neuropsychiatric effects suggest gabapentin has inherent delirium-promoting properties through CNS depression.
Clinical Research Evidence
Increased Delirium Risk in Surgical Patients
The most robust evidence comes from a 2022 retrospective cohort study of 967,547 older surgical patients (mean age 76.2 years) 2. After propensity score matching:
- Gabapentin users had 28% higher risk of delirium (RR 1.28,95% CI 1.23-1.34)
- Absolute risk increase: 0.75 additional delirium cases per 100 patients
- Risk was substantially higher in vulnerable subgroups:
- High comorbidity burden (combined index ≥4): RR 1.40 vs 1.20 in low burden
- Chronic kidney disease: RR 1.38 with absolute increase of 1.97 per 100 patients
- Also increased pneumonia risk (RR 1.11) and new antipsychotic use (RR 1.17)
This large, well-controlled study provides the strongest evidence that gabapentin contributes to delirium in older adults 2.
Contradictory Evidence in Specific Populations
A 2017 randomized controlled trial of 697 surgical patients (mean age 72 years) found no reduction in postoperative delirium with gabapentin 900 mg perioperatively (24.0% vs 20.8% placebo, p=0.30) 3. While this study was designed to test whether gabapentin prevents delirium through opioid-sparing effects, the similar delirium rates suggest gabapentin's opioid-sparing benefit does not offset its direct delirium risk.
Interestingly, one 2022 Japanese study of 143,132 older cancer patients undergoing chemotherapy found gabapentinoid use associated with reduced hyperactive delirium (5.2% vs 8.5%, OR 0.60) 4. However, this contradictory finding likely reflects confounding by indication—cancer patients receiving gabapentinoids may have had better pain control overall, reducing delirium from undertreated pain.
Database Analyses Confirm Association
A 2024 FAERS database analysis of 2,950 delirium reports found gabapentinoids had higher reporting rates for delirium (ROR 1.09) and delirium tremens (ROR 1.54) 5. Risk was particularly elevated in patients ≥65 years and males. When confounders like opioid co-administration were removed, the signal weakened but remained present in elderly populations.
A 2025 MIMIC-IV database study of 12,327 ICU patients aged ≥60 found pregabalin (a related gabapentinoid) associated with 72-91% increased delirium risk across multiple models (OR 1.72-1.91) 6. Risk was significantly higher in patients not receiving analgesia, suggesting gabapentinoids may cause delirium independent of pain control benefits.
Clinical Algorithm for Decision-Making
When considering gabapentin in patients at risk for delirium:
Assess baseline delirium risk factors:
- Age ≥75 years
- Chronic kidney disease (requires dose adjustment and increases delirium risk)
- High comorbidity burden (combined index ≥4)
- Male sex
- Cognitive impairment or prior delirium
If 2+ high-risk factors present:
- Strongly consider alternative analgesics (acetaminophen, NSAIDs if appropriate, topical agents)
- If gabapentin necessary, start at lowest dose (100-300 mg/day) rather than standard 900-1800 mg/day
- Monitor closely for early delirium signs using validated tools (CAM-ICU, ICDSC)
If gabapentin prescribed:
- Adjust dose for renal function (critical—gabapentin is renally cleared)
- Avoid combining with other CNS depressants when possible
- Educate caregivers about delirium symptoms (confusion, agitation, altered consciousness)
- Consider prophylactic non-pharmacologic delirium prevention (reorientation, sleep hygiene, early mobilization)
If delirium develops:
- Discontinue or reduce gabapentin dose as first-line intervention
- Do not abruptly stop (taper over 1 week minimum to prevent withdrawal seizures) 1
- Address other reversible causes per standard delirium workup
Important Caveats
Gabapentin should not be abruptly discontinued due to risk of withdrawal seizures, even in patients without epilepsy 1. Taper over at least one week.
The opioid-sparing effects of gabapentin do not appear to offset its direct delirium risk in older adults 2, 3. The net effect is increased delirium despite reduced opioid exposure.
One small retrospective study suggested gabapentin might treat delirium (71.8% improvement at 2 days) 7, but this conflicts with higher-quality evidence and likely reflects selection bias. This should not guide routine practice.
The evidence consistently shows gabapentin contributes to delirium in older adults, particularly those with renal impairment or high comorbidity burden 2, 5, 6. Use cautiously in these populations, start with low doses, and maintain high vigilance for delirium development.